Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Waldmann Website

Thomas A. Waldmann, M.D.

Selected Publications

1)  Shah NN, Waldmann TA.
GVL for ATL?.
Blood. 121: 6-7, 2013.
[Journal]
2)  Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, Conlon KC, Keating A, Waldmann TA.
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
Blood. 121: 2029-37, 2013.
[Journal]
3)  Waldmann TA, Conlon KC, Stewart DM, Worthy TA, Janik JE, Fleisher TA, Albert PS, Figg WD, Spencer SD, Raffeld M, Decker JR, Goldman CK, Bryant BR, Petrus MN, Creekmore SP, Morris JC.
Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia.
Blood. 121: 476-84, 2013.
[Journal]
4)  Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E, Price DA, Waldmann TA, Restifo NP, Franchini G, Roederer M.
Superior T memory stem cell persistence supports long-lived T cell memory.
J. Clin. Invest. 123: 594-9, 2013.
[Journal]
5)  Yokoyama S, Perera PY, Waldmann TA, Hiroi T, Perera LP.
Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.
J. Clin. Immunol. 33: 586-94, 2013.
[Journal]
6)  Zhang M, Ju W, Yao Z, Yu P, Wei B, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA.
Augmented IL-15Ralpha Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice.
J Immunol. 188: 6156-64, 2012.
[Journal]
7)  Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature. 490: 116-20, 2012.
[Journal]
8)  Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM.
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.
Cancer Cell. 21: 723-37, 2012.
[Journal]
9)  Chen J, Petrus M, Bamford R, Shih JH, Morris JC, Janik JE, Waldmann TA.
Increased serum soluble IL-15Ralpha levels in T-cell large granular lymphocyte leukemia.
Blood. 119: 137-43, 2012.
[Journal]
10)  Steel JC, Waldmann TA, Morris JC.
Interleukin-15 biology and its therapeutic implications in cancer.
Trends Pharmacol. Sci. 33: 35-41, 2012.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 5/2/2013.